NCT05662943Completed
Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCV
Tolerating Subretinal Fluid in Type 1 Macular Neovascularization and Polypoidal Choroidal Vasculopathy Treated Using Aflibercept
Source: ClinicalTrials.gov · Last updated 14 Dec 2023
Brief summary (registry, in English)
The purpose of the present study was to evaluate the outcomes of type 1 macular neovascularization (MNV), including polypoidal choroidal vasculopathy in patients treated tolerating subretinal fluid (SRF) using Aflibercept in a clinical setting. Approximately 150 patients are anticipated to be enrolled in this study. SRF is a primary type of fluid compartment prevalent in type 1 aneurysmal MNV. In a recent study, the prevalence of SRF during 24-month follow-up period was 36.7% to 38.8% in type 1 MNV and polypoidal choroidal vasculopathy (PCV), 20.0% in type 2 MNV, and 7.7% in type 3 MNV. In addition, patients with SRF showed better visual prognosis in type 1 MNV/PCV. For this reason, type 1 MNV is an appropriate candidate for evaluating the influence of tolerating SRF.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 135 (actual)
- First submitted
- 9 Dec 2022
- Start date
- 5 Dec 2022
- Primary completion date
- 31 May 2023
- Lead sponsor
- Kim's Eye Hospital
- Diseases
- Macular degeneration
- NCT number
- NCT05662943
What you commit to
- Study type: Observational
- Participants enrolled: 135
- From 5 Dec 2022 to the primary completion date, 31 May 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who received other treatment for neovascular age-related macular degeneration (AMD), except for aflibercept (eg. ranibizumab, bevacizumab, or PDT)
Other illness
- History of intraocular or periocular steroid injection
- History of vitreoretinal surgery or glaucoma surgery
- History of intraocular inflammation
Other
- Less than 6 months of tolerating-fluid phase
- Patients without indocyanine green angiography (ICGA) result
- Uncontrolled glaucoma (IOP ≥ 25mmHg)
Who the study is looking for
- Patient who were diagnosed with type 1 MNV or PCV
- Patients who were treated using aflibercept between January 2021 and December 2022
- Patients underwent continuous aflibercept injections with tolerating subfoveal retinal fluid more than 6 months.
Age in the registry: 50 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Jae Hui Kim Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.